The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.n

ILD with a granulomatous component

Publications

Burns AM, Green PJ, Pasternak S

Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab.

Journal of cutaneous pathology 2012 Feb;39;289-93 — 2012 Feb — 289-93

Toussirot E, Pertuiset E

[TNF? blocking agents and sarcoidosis: an update].

La Revue de medecine interne 2010 Dec;31;828-37 — 2010 Dec — 828-37

Phillips K, Weinblatt M

Granulomatous lung disease occurring during etanercept treatment.

Arthritis and rheumatism 2005 Aug 15;53;618-20 — 2005 Aug 15 — 618-20

Vavricka SR, Wettstein T, Speich R, Gaspert A, Bachli EB

Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy.

Thorax 2003 Mar;58;278-9 — 2003 Mar — 278-9